Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

This study aimed to analyze and compare the application of FISH and IHC in BC tissue Her-2 / neu gene amplification or expression. For this purpose, 110 patients with BC were selected. FISH and IHC were performed on the BC tissues that were surgically removed, and the results were compared and analyzed. The results showed that in 110 BC tissues, the expression of HER-2 protein was (+++) 25 cases (22.73%); (++) 44 cases (40%); (+) 26 cases (23.64%); (1) 15 cases (13.64%). There were 42 cases of HER-2 gene amplification in 110 BC tissues, and 68 cases had no amplification. IHC test positive (+++) is consistent with FISH positive coincidence rate, IHC test negative (+/-) is consistent with FISH negative coincidence rate, IHC test suspicious positive (++) compared with the FISH result, the difference is statistically significant. However, the total coincidence rate between IHC test results and FISH test results was 89.29 (25/28), and the two test methods were positively correlated. Generally, IHC positive and negative expressions are in good agreement with FISH test results. The suspected positive expression of IHC is inconsistent with the FISH test result, suggesting that the IHC test is suspicious, and the positive specimens need to be tested by FISH.

Download full-text PDF

Source
http://dx.doi.org/10.14715/cmb/2021.67.5.52DOI Listing

Publication Analysis

Top Keywords

ihc test
20
gene amplification
12
coincidence rate
12
rate ihc
12
fish test
12
ihc
10
fish
10
test
9
amplification expression
8
expression ihc
8

Similar Publications

PD-L1 expression in locally advanced cervical cancer: A pilot cross clone comparison study.

Int J Radiat Oncol Biol Phys

September 2025

Department of Radiation Oncology, Advanced Centre for Treatment Research and Education in Cancer, Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, India. Electronic address:

Purpose: Recent immunotherapy trials in locally advanced cervical cancer report high PD-L1 positivity rates whereas academic multicentric initiatives report a lower PD-L1 positivity. These observations necessitate cross-clone comparison to understand the observed differences.

Methods: Two different clones used in previous multicentric international studies SP142 (BIOEMBRACE) and 22C3 (KEYNOTE-A18) were used to test PD-L1 positivity in a pilot cohort of FIGO 2018 stage III cervical cancer patients recruited in a phase III trial.

View Article and Find Full Text PDF

HER2DX ERBB2 score in advanced HER2-positive gastric cancer treated with trastuzumab and chemotherapy.

ESMO Open

September 2025

Department of Medical Oncology, Hospital Clínic Barcelona, Barcelona, Spain; Translational Genomics and Targeted Therapies in Solid Tumors, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain; Faculty of Medicine, University of Barcelona, Barcelona, Spain; Clínic Barcelona

Background: Response to trastuzumab combined with chemotherapy (T-chemo) in human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer (AGC) varies widely, highlighting the need for more precise biomarkers beyond conventional HER2 assessment with immunohistochemistry (IHC) and in situ hybridization (ISH). The HER2DX ERBB2 messenger RNA (mRNA) assay, a clinically validated genomic test initially developed for early-stage HER2-positive breast cancer, quantitatively measures ERBB2 expression and may improve patient selection for T-chemo in AGC.

Patients And Methods: In a retrospective cohort of 134 patients with AGC, including 58 who received T-chemo, we evaluated whether the HER2DX ERBB2 score defines more accurately HER2 status and correlates with treatment response and survival outcomes in HER2-positive AGC, compared with standard pathology-based methods.

View Article and Find Full Text PDF

Purpose: The mammalian cochlea has two types of low abundance and highly specialized inner (IHC) and outer (OHC) mechanosensory hair cells. Their malfunction or death is a common cause of congenital and acquired deafness. IHCs and OHCs exhibit different transcriptomes during development.

View Article and Find Full Text PDF

Association of the BRAFV600E mutation with morphology and heterogeneity in melanoma.

Lab Invest

September 2025

Department of Pathology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou 350014, China. Electronic address:

The BRAFV600E mutation test for melanoma patients has become the key to precision therapy.Comparing the concordance of immunohistochemistry (IHC), quantitative real-time polymerase chain reaction (qPCR), and next-generation sequencing (NGS) in detecting the BRAFV600E mutation in a Chinese melanoma patient population. In addition, evaluating BRAFV600E mutation heterogeneity between primary and metastatic melanoma sites and within the same lesion, and investigating the association between BRAFV600E mutation status and tumor cell morphology.

View Article and Find Full Text PDF

Background Non-clear cell renal cell carcinomas (nccRCCs) are a histologically heterogeneous and clinically underrepresented group of renal malignancies, distinct from clear cell RCC in morphology, molecular profile, and prognosis. Despite accounting for 20-30% of RCCs, nccRCC subtypes are infrequently studied, especially in the Indian population. This study aimed to evaluate the clinicopathological features, immunohistochemical patterns, and oncological outcomes of primary nccRCCs in a tertiary care setting.

View Article and Find Full Text PDF